(19)
(11) EP 1 681 063 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 158(3) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
02.11.2006 Bulletin 2006/44

(43) Date of publication:
19.07.2006 Bulletin 2006/29

(21) Application number: 04771663.4

(22) Date of filing: 13.08.2004
(51) International Patent Classification (IPC): 
A61K 38/18(2006.01)
A61P 25/00(2006.01)
 A61P 9/00(2006.01)
A61P 25/28(2006.01)
(86) International application number:
PCT/JP2004/011696
(87) International publication number:
WO 2005/034985 (21.04.2005 Gazette 2005/16)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 14.10.2003 JP 2003354411

(71) Applicants:
  • Takeo, Satoshi
    Yamanashi 409-0126 (JP)
  • Nakamura, Toshikazu
    Kyoto 606-8333 (JP)
  • Kringle Pharma Inc.
    Toyonaka-shi, Osaka 560-0082 (JP)

(72) Inventors:
  • TAKEO, Satoshi
    Yamanashi 409-0126 (JP)
  • NAKAMURA, Toshikazu
    Kyoto-shi, Kyoto 6068333 (JP)
  • TAKAGI, Keiko
    Hino-shi, Tokyo 192-0024 (JP)
  • TAKAGI, Norio
    Hino-shi, Tokyo 192-0024 (JP)

(74) Representative: Findeisen, Marco et al
Witte, Weller & Partner Patentanwälte Postfach 105462
70047 Stuttgart
70047 Stuttgart (DE)

   


(54) AGENT FOR IMPROVING MENTAL DISORDERS


(57) The present invention relates to an agent for improving a mental disorder due to cerebral dysfunction, an agent for inhibiting vascular hyperpermeability, a composition for improving a mental disorder due to cerebral dysfunction, a composition for inhibiting vascular hyperpermeability, a method of improving a mental disorder due to cerebral dysfunction, a method of inhibiting vascular hyperpermeability, and the use of a hepatocyte growth factor in producing a pharmaceutical preparation.